Search - tctmd.com

Displaying 141 - 160 of 696

Sort: Relevancy | Date

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and Vorapaxar Should Be Considered!

Presenter: C. Michael Gibson, Marco Valgimigli, Ori Ben-Yehuda

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Neal S. Kleiman

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Robert W. Yeh

October 11, 2015

News Daily News

ADAPT-DES Substudy: Practice Changes May Decrease Already Low Stent Thrombosis Rates Even Further

Yael L. Maxwell

October 09, 2015

News Daily News

Reduced Leaflet Motion in Bioprosthetic Aortic Valves Not Uncommon But Remedied by Anticoagulation

L.A. McKeown

October 08, 2015

News Industry News

Boston Scientific Receives FDA Approval For SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System

October 05, 2015

News Daily News

Good Outcomes of Novel Bioresorbable-Polymer SES Persist at 2 Years

Yael L. Maxwell

October 02, 2015

News Industry News

Neuravi Announces European Launch of Innovative Minimally Invasive Stroke Therapy

October 01, 2015

News Opinion Fellow Talk

The Faith of ‘Investing’ in Chronic Total Occlusion Interventions

Henry Quevedo, MD

September 22, 2015

News Industry News

CeloNova Announces FDA Approval to Start a Randomized Trial for the COBRA PzF™ Coronary Stent System

September 21, 2015

News Daily News

RECLOSE-3: Shifting Clopidogrel Nonresponders to Prasugrel Lowers Mortality After PCI

Yael L. Maxwell

September 18, 2015

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Industry News

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

September 09, 2015

News Conference News ESC 2015

EXAMINATION: STEMI Patients Fare Better at 5 Years With EES vs BMS

Caitlin E. Cox

September 02, 2015

News Conference News ESC 2015

DAPT Analysis Eases Concerns Over Slightly Higher Death Rate Seen With Extended Thienopyridine Use

Caitlin E. Cox

September 01, 2015

Presentation ESC 2015

Long-term Dual Antiplatelet Therapy for 2° Prevention of Cardiovascular Events in Patients with Previous Myocardial Infarction

Presenter: Jacob A. Udell

August 31, 2015

Presentation ESC 2015

12 vs 48 months of dual antiplatelet therapy after drug-eluting stent placement: The OPTIDUAL Randomized Trial

Presenter: G?rard Helft

August 31, 2015

News Daily News

SES Fracture Linked to Worse Long-term Outcomes

August 31, 2015

News Conference News ESC 2015

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

Caitlin E. Cox

August 31, 2015

News Conference News ESC 2015

Meta-analysis: Long-Term DAPT Beneficial for Patients With History of MI

Yael L. Maxwell

August 31, 2015

Advertisement

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and Vorapaxar Should Be Considered!

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)!

ADAPT-DES Substudy: Practice Changes May Decrease Already Low Stent Thrombosis Rates Even Further

Reduced Leaflet Motion in Bioprosthetic Aortic Valves Not Uncommon But Remedied by Anticoagulation

Boston Scientific Receives FDA Approval For SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System

Good Outcomes of Novel Bioresorbable-Polymer SES Persist at 2 Years

Neuravi Announces European Launch of Innovative Minimally Invasive Stroke Therapy

The Faith of ‘Investing’ in Chronic Total Occlusion Interventions

CeloNova Announces FDA Approval to Start a Randomized Trial for the COBRA PzF™ Coronary Stent System

RECLOSE-3: Shifting Clopidogrel Nonresponders to Prasugrel Lowers Mortality After PCI

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

EXAMINATION: STEMI Patients Fare Better at 5 Years With EES vs BMS

DAPT Analysis Eases Concerns Over Slightly Higher Death Rate Seen With Extended Thienopyridine Use

Long-term Dual Antiplatelet Therapy for 2° Prevention of Cardiovascular Events in Patients with Previous Myocardial Infarction

12 vs 48 months of dual antiplatelet therapy after drug-eluting stent placement: The OPTIDUAL Randomized Trial

SES Fracture Linked to Worse Long-term Outcomes

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

Meta-analysis: Long-Term DAPT Beneficial for Patients With History of MI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content